It's wegovy safe?

Grok 4.1 Fast

Vote: Yes

I maintain my vote for A. Wegovy is FDA-approved with a proven safety profile in large trials (STEP, SELECT), showing significant benefits like 15-20% weight loss and 20% CV risk reduction, far outweighing manageable GI side effects and rare risks. GPT-5.4's B argument overemphasizes risks without context—no drug is risk-free, but 'safe' means acceptable risk-benefit under medical supervision, as affirmed by approvals. Their 'unconditional' framing ignores this standard, making B an absolute dismissal unsupported by evidence. A voters (Claude, Gemini, Kimi) reinforce with trials, real-world data, and regulatory rigor; none sway to B, as risks are monitored, not prohibitive. Blanket 'No' misleads; Wegovy is safe for intended use.

GPT-5.4

Vote: No

I maintain vote B. The pro-A arguments correctly note that Wegovy is FDA-approved and can be safe for its intended use under clinician supervision. But the actual question is a bare, consumer-style binary: "It's wegovy safe?" Without qualifiers, answering "Yes" overstates certainty and ignores important contraindications, warnings, and person-specific risk. Regulatory approval does not mean universally safe. It means the benefits outweigh the risks for a defined population when used as directed. That is a narrower claim than an unqualified yes. The other models' strongest point is risk-benefit framing, but that framing actually supports my objection to A: safety is conditional. Wegovy has common adverse effects and meaningful serious risks, including gallbladder disease, pancreatitis risk, dehydration-related kidney injury, and a boxed warning tied to thyroid C-cell tumors in animals. It is also inappropriate for some patients. So if forced into A/B, B is the more accurate answer because "Yes" is too absolute. The truthful short version is: not simply yes; it can be safe for some people with proper medical supervision.

Claude Opus 4.6

Vote: Yes

I maintain my vote of A (Yes). GPT-5.4's argument for B raises valid points about Wegovy's side effects and contraindications, but ultimately applies an unreasonable standard. By GPT-5.4's logic, virtually no FDA-approved medication could be called 'safe' — not aspirin, not acetaminophen, not statins, not antibiotics — because all carry risks, contraindications, and require appropriate use. The question 'Is Wegovy safe?' is reasonably interpreted as asking whether it has an acceptable safety profile for its intended use. The answer is clearly yes: it is FDA-approved after rigorous Phase 3 trials, it has a well-characterized and manageable side effect profile, it demonstrated cardiovascular benefits in the SELECT trial, and millions of patients have used it under medical supervision with favorable outcomes. Saying 'No, Wegovy is not safe' would be misleading and could discourage people with obesity — a serious chronic disease — from seeking effective treatment. The consensus among four out of five models here reflects the medical consensus: Wegovy is safe when used as directed under medical supervision. That is the standard meaning of 'safe' for any medication.

Gemini 3.1 Pro

Vote: Yes

I am maintaining my vote for 'A' (Yes). GPT-5.4 makes a fair point that Wegovy has side effects and contraindications, but their argument applies a standard of 'unconditional safety' that no prescription medication on earth can meet. In medicine and pharmacology, a drug is considered 'safe' when regulatory bodies (like the FDA) determine its clinical benefits outweigh its potential risks when used as prescribed under medical supervision. Wegovy has passed these rigorous evidentiary thresholds. Furthermore, as Claude Opus 4.6 highlighted, Wegovy has demonstrated significant cardiovascular benefits (reducing adverse events by 20% in specific populations), which actively improves patient safety and longevity. Therefore, the most accurate binary answer is 'Yes,' as voting 'No' would incorrectly imply the drug is inherently dangerous or unapproved.

Kimi K2.5

Vote: Yes

GPT-5.4 raises valid points about conditional safety, but in the binary choice between 'safe' and 'unsafe,' the medical and regulatory consensus clearly supports 'Yes.' In pharmacology, 'safe' never means 'risk-free'—it means the benefits outweigh the risks under appropriate medical supervision. Wegovy's FDA approval, extensive STEP trial data, and real-world post-marketing surveillance establish this favorable risk-benefit profile. Choosing 'No' would imply the drug is generally unsafe or contraindicated for all, which contradicts the evidence. While individual eligibility varies (thyroid history, pancreatitis risk), this is true of virtually all medications. The presence of a black-box warning or side effects doesn't negate safety—it defines the parameters within which the drug is safe to use. The SELECT trial data showing 20% cardiovascular risk reduction further supports that Wegovy offers net health benefits beyond weight loss alone. For eligible patients under physician monitoring, Wegovy meets the established threshold for safety.

Final Summary

The AI Roundtable reached a decisive 4-1 majority in favor of Wegovy's safety, though the debate exposed a deep philosophical divide over the word 'safe.' While GPT-5.4 stood alone as a semantic holdout, arguing that a binary 'Yes' ignores significant contraindications and risks, the rest of the group—led by Claude Opus 4.6 and Gemini 3.1 Pro—dismissed this as an impossible standard that would render even aspirin 'unsafe.' The majority successfully framed safety not as an absence of risk, but as a favorable risk-benefit ratio backed by FDA approval and impressive cardiovascular data.

Majority chose "Yes" after discussion (4/5). Final vote: Yes: 4, No: 1

Strongest Arguments

• Yes: The SELECT trial showed Wegovy reduced major adverse cardiovascular events by 20%, proving the drug doesn't just manage weight but actively improves patient longevity and heart health.
• No: A bare 'Yes' to a consumer-style question overstates certainty and ignores the boxed warnings and specific medical conditions that make the drug inappropriate for many individuals.

Key Turning Points

• Claude Opus 4.6 challenged GPT-5.4's logic by noting that if 'safe' required unconditional risk-free status, virtually no medication on earth could be approved.
• The introduction of the SELECT trial data by Claude and Gemini provided a empirical anchor for the 'Yes' camp, moving the argument from weight loss to life-saving cardiovascular benefits.